ROS1 and non-small cell lung carcinoma: In this study, we analyzed the clinicopathological characteristics and disease progression patterns of NSCLC patients with different ROS1 gene fusion variants who received first‐line treatment with either crizotinib or platinum‐based chemotherapy.